SION-2222 galicaftor Updated Nov 10
The next catalyst is the initiation of the AscenSION CF Phase 2a proof-of-concept trial for the SION-451 + SION-2222 dual combination, expected in Q1 2027. If the trial starts on schedule, it signals the company is executing on its restructuring plan; a delay would raise concerns given the company's single-asset focus. The actual Phase 2a topline readout is likely 12+ months after initiation and represents the true binary event for the stock.
- SION-2222 (galicaftor) is a TMD1-directed CFTR corrector that, combined with the NBD1 stabilizer SION-451, showed a well-tolerated safety profile in Phase 1 healthy volunteer dosing; in the SION-451 + SION-2222 cohorts most treatment-emergent adverse events were mild to moderate and no serious adverse events were reported.
- The company has $249.8M in cash and securities as of Q3 2026, funding operations into H2 2029 and removing near-term dilution risk while the dual combination advances.
- Sionna cut 46% of its workforce in September 2026 to focus exclusively on the SION-451 + SION-2222 dual combination, concentrating all resources on this single program.
- SION-2222 has never been tested in CF patients; the Phase 1 trial was only in healthy volunteers, so efficacy is entirely unproven.
- The company's prior lead candidate SION-719 failed its Phase 2a endpoint in August 2026, eroding confidence in the NBD1 stabilizer platform and raising questions about whether SION-451 (the partner drug) will work.
- Vertex Pharmaceuticals (VRTX) dominates the CF market with Trikafta, and Sionna's dual combination would need to show a compelling efficacy and safety profile to compete or carve out a niche.